Anti-amyloidogenic therapies: strategies for prevention and treatment of Alzheimer’s disease
- First Online:
- Cite this article as:
- Hamaguchi, T., Ono, K. & Yamada, M. Cell. Mol. Life Sci. (2006) 63: 1538. doi:10.1007/s00018-005-5599-9
- 334 Downloads
Deposition of amyloid β-protein (Aβ) in the brain is an early and invariant neuropathological feature of Alzheimer’s disease (AD). The current search for anti-AD drugs is mainly focused on modification of the process of accumulation of Aβ in the brain. Here, we review four anti-amyloidogenic strategies: (i) reduction of Aβ production, which has mainly been approached with secretase inhibition, (ii) promotion of the Aβ degrading catabolic pathway, including an Aβ degrading enzyme, neprilysin, (iii) immunotherapy for Aβ and (iv) inhibition of Aβ aggregation. We have reported that AD patients have a favorable molecular environment for Aβ aggregation and that various compounds, such as polyphenols, interfere with Aβ aggregation and destabilize preformed Aβ fibrils.